Lung Cancer Research Foundation (LCRF): Boehringer Ingelheim Team Science Award on Innovative Therapeutic Strategies to Understand and Treat Lung Cancers Harboring HER2 Mutations – LOIs

will focus on the science behind HER2 mutations as oncogenic drivers of malignancy and/or the development of novel therapeutic approaches for patients with tumors harboring HER2 mutations.

Funding: $1,500,000 over a period of three years

website